PRAME and cancer: Collectively, our findings support a potential dual purpose for targeting of PRAME in cancer; either through direct targeting of cancer cells based on PRAME immunogenicity or by inhibiting oncogenic traits of PRAME, or through indirect disruption of PRAME‐associated immunomodulation.